Related Experiment Video

Updated: May 25, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors

H Makishima1, Y Sugimoto, H Szpurka

  • 1Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH 44195, USA.

Leukemia
|January 17, 2012
PubMed

Insights

CBL mutations in myeloid cancers impair signaling pathways. Dual SRC and RTK inhibitors, like dasatinib, effectively target these mutations, offering a promising therapeutic strategy.

Area of Science:

  • Oncology
  • Molecular Biology
  • Signal Transduction

Background:

  • CBL mutations reduce ubiquitin ligase activity, affecting SRC family kinases (SFK) and receptor tyrosine kinases (RTK).
  • The specific SFK and RTK targets most impacted by CBL mutations remain unclear, hindering precise therapeutic strategies.

Purpose of the Study:

  • To compare SFK and RTK pathway activity and inhibitor responses in acute myeloid leukemia (AML) cell lines with varying CBL mutations.
  • To identify the most effective therapeutic targets for AML with CBL-inactivating mutations.

Main Methods:

  • Utilized AML cell lines with homozygous R420Q CBL mutation (GDM-1), heterozygous deletion (MOLM13), and wild-type (WT) CBL (THP1, U937).
  • Assessed SFK and RTK pathway activity and sensitivity to inhibitors including dasatinib, sunitinib, imatinib, and PP2.
  • Performed phosphoprotein analysis to identify dasatinib-inhibited targets in GDM-1 cells.

Main Results:

  • GDM-1 cells exhibited high KIT expression and granulocyte-macrophage colony-stimulating factor (GM-CSF) hypersensitivity, characteristic of CBL loss.
  • GDM-1 cells showed high sensitivity to dasatinib (dual SFK/RTK inhibitor), unlike other cell lines or those treated with RTK or SFK-specific inhibitors.
  • Dasatinib uniquely inhibited phosphorylation of KIT and GM-CSF receptor pathway proteins (e.g., KIT Tyr721, STAT3 Tyr705) in GDM-1 cells.

Conclusions:

  • CBL loss broadly affects SFK and RTK signaling in AML.
  • Dual inhibition of SFK and RTK pathways is the most effective strategy for targeting AML with CBL-inactivating mutations.

More Related Videos

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays07:42

Assessment of Resistance to Tyrosine Kinase Inhibitors by an Interrogation of Signal Transduction Pathways by Antibody Arrays

Published on: September 19, 2018

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

Related Concept Videos

Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...